Reported Biomarkers
Currently showing all called biomarkers, show actionable biomarkers only.
Switch table layout to show biomarkers as columns, and tests as rows.
| Biomarker | Testing Runs | Annotation | ||
|---|---|---|---|---|
DNATests Germline NGS 2023-01-15 | MyLabCo Liquid Biopsy 2023-08-01 | MyLabCo Liquid Biopsy 2024-01-24 | ||
| ATM | Tested, mutated | Not tested | Not tested | |
| BRCA2 | Tested, not mutated | Tested, mutated | Tested, mutated | BRCA2 can be mutated both in the germline or in a patient’s tumor. About 7% of prostate cancer patients have acquired a BRCA2 mutation. Patients with either germline or somatic BRCA2 mutations may be eligible to take a PARP inhibitor. |
| NF1 | Not tested | Not tested | Tested, mutated | NF1 is a gene in the RAS/MAPK pathway that is occasionally mutated in patients with prostate cancer. While there are no FDA approved medications that target NF1-mutated prostate cancer, there are several clinical trials evaluating targeted treatments for patients with NF1 mutations. |
| TMB | Not tested | Tested, mutated (High) | Tested, mutated (High) | Elevated TMB is uncommon (<5% of patients) in prostate cancer. Patients with high TMB often respond well to checkpoint inhibitors. |